Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
NCT ID: NCT06299553
Last Updated: 2024-05-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
200 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-12-04
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268
Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
ACTIVE_NOT_RECRUITING
PHASE3
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Diffuse Large B-cell Lymphoma
RECRUITING
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05552937
DLBCL
RECRUITING
PHASE2
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT04697160
Diffuse Large B Cell Lymphoma
COMPLETED
Lenalidomide Monotherapy in R/R DLBCL
NCT04150328
Diffuse Large B Cell Lymphoma
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an Italian, multicenter, prospective observational cohort study to collect data on patients with non-transplant eligible R/R DLBCL treated with tafasitamab plus lenalidomide followed by tafasitamab in monotherapy, as second, third and fourth treatment line in a real-world clinical practice setting.
The study is non-interventional; all treatment decisions are made at the discretion of the patient's healthcare provider and are not mandated by the study design or protocol.
Since this is an observational study of real-world treatment practices and outcomes, no study medication will be provided as a part of this study. Tafasitamab and lenalidomide will be provided through usual commercial channels for medicines prescription. Tafasitamab and lenalidomide will not be provided free of charge by the sponsor.
Physicians will make all treatment decisions according to their usual clinical practices and will provide prescriptions for their patients as appropriate. The decision to treat the patient with tafasitamab must have been taken prior to and independently of the patient's inclusion in the study. There are no mandatory protocol procedures or diagnostic tests.
This is a prospective observational study: patients will be eligible to enter the study if the treatment with tafasitmab plus lenalidomide is started and when all the ethical and contract procedures with the site have been completed and after the site initiation visit date.
The study will be performed in approximately 30 Italian sites distributed in the overall Italian territory.
During this study, patients must completed questionnaires of quality of life. Questionnaires should be completed by the patient Electronic Patient Reported Outcome (ePRO)at each applicable occasion. Where possible in accordance with local clinical practice, PROs should be completed before other assessments. The following measures are requested to be recorded:
* EORTC-QLQ-C30 (Version 3).
* EORTC QLQ NHL-HG29
The standardized EORTC QLQ-C30 questionnaire (v. 3.0) was used to assess the HRQoL of cancer patients. The questionnaire contains questions regarding the impact of the disease on different areas of a patient's life (physical, role, emotional, cognitive, and social functioning), the occurrence of symptoms (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea), financial difficulties, and an overall assessment of HRQoL (Appendix 4). (Aaronson NK, Ahmedzai S, Bergman B, et al. 1993). For each question, the respondent must choose 1 answer. For 28 of the questions, the answers are given on a 4-point Likert-type scale (1 - never, 2 - sometimes, 3 - often, 4 - very often) and assess the intensity of the analysed parameters. The last 2 questions evaluate the general health of the patient on a 7-point scale (from 1 - very bad to 7 - excellent). Patients completed the questionnaires by themselves. If a question arose, they could ask the researcher for an explanation.
After collecting the responses, a raw score was calculated for each of the abovementioned 15 questionnaire items. Next, a linear transformation was performed to obtain a score in a range from 0 to 100. The conversion of the results to a 100-point scale was made according to the EORTC guidelines. Of note, a higher score on the functional scales means better functioning and a higher response for general health corresponds to a better HRQoL.
The QLQ-HG-NHL29 consists of 29 items, contributing to five multiitem subscales and three conditional items: symptom burden due to disease and/or treatment (seven items), neuropathy (two items), physical condition/fatigue (five items), emotional impacts (four items) and worries about health and functioning (eight items). The three conditional items, which patients complete only if relevant to them, are about having problems at work/education, worries about work/education and concerns about the ability to have children. (Appendix 5) (Van de Poll-Franse L, Oerlemans S, Bredart A, et al. 2018) Items are rated using a four-point response scale ("not at all," "a little," "quite a bit," and "very much") and the reference time frame for all items is the past week.14 The scoring approach for the QLQ-HG-NHL29 is identical to that of the EORTC QLQ-C30, i.e., calculating the mean of the items of a specific multi-item scale or using the single conditional item score and then converting it into a standardized scale ranging from 0 to 100. A higher score for all the multi-item scales and items represent a higher level of symptomatology or problems.
HRQoL questionnaires will be filled out either at the hospital or during pre-scheduled medical office visits. The questionnaires will be provided to the patient by a member of the study team at the scheduled times to coincide with other scheduled assessments or visits, via standard paper copy administration. However, HRQoL electronic questionnaires administration may be allowed as a back-up procedure, to maximize compliance. Patients will be asked to fill out the questionnaires as completely and accurately as possible with an expected average time of completion around 10 minutes.
A high compliance with HRQoL questionnaires throughout the study period is considered essential for the success of this observational study and local Investigators of participating centers will have to be properly informed and motivated towards the importance of collecting HRQoL data.
Each participating center will be requested to submit a HRQoL Missing Data Form in lieu of a HRQoL questionnaire for any assessment that is not provided at the appropriate follow-up time point. Compliance with HRQoL questionnaires over time will be monitored (not for the purpose of informing clinical care of participants) and, if needed, reminders will be sent to participating centers to solicit HRQoL data. The compliance rate at each time point will be evaluated as the number of valid HRQoL questionnaires returned by eligible patients as a proportion of the total number of eligible patients available.
In order to make the HRQoL component of the study as pragmatic as possible, and not to undermine the data collection process across several centers, HRQoL assessment is requested to take place in conjunction with the collection of effectiveness data foreseen for this protocol.
Therefore, HRQoL questionnaires will be administered at baseline (before first tafasitamab administration) and then every 3 months during the first year, and then every 6 months thereafter, unless the patient has a disease progression and/or permanently discontinue treatment with tafasitamab. The first HRQoL assessment after baseline, would correspond to the end of the period where tafasitamab is administered on a weekly basis (approximately at the end of cycle 3), hence with potential expected HRQoL detriments. Thereafter, (starting from cycle 4) considering the infusions of tafasitamab will take place every 2 weeks, HRQoL improvements (although with not known magnitude) could possibly be expected and captured in this study. HRQoL will be assessed regardless of dose modification or temporary treatment interruption, as long as the patient is considered "on study" according current protocol definition.
In case of temporary treatment interruption:
Continue HRQoL assessment as described in the above schedule of administration.
In case of permanent treatment discontinuation with tafasitamab:
HRQoL assessment should be performed at the time of discontinuation (in any case as close as possible to the time of treatment discontinuation) and then stopped afterwards.
In case of disease progression:
HRQoL assessment should be performed at the time of progression (in any case as close as possible to the time of disease progression) and then stopped afterwards.
The study is non-interventional; all treatment decisions are made at the discretion of the patient's healthcare provider and are not mandated by the study design or protocol.
Since this is an observational study of real-world treatment practices and outcomes, no study medication will be provided as a part of this study. Tafasitamab and lenalidomide will be provided through usual commercial channels for medicines prescription. Tafasitamab and lenalidomide will not be provided free of charge by the sponsor.
Physicians will make all treatment decisions according to their usual clinical practices and will provide prescriptions for their patients as appropriate. The decision to treat the patient with tafasitamab must have been taken prior to and independently of the patient's inclusion in the study. There are no mandatory protocol procedures or diagnostic tests.
This is a prospective observational study: patients will be eligible to enter the study if the treatment with tafasitmab plus lenalidomide is started and when all the ethical and contract procedures with the site have been completed and after the site initiation visit date.
The study will be performed in approximately 30 Italian sites distributed in the overall Italian territory.
During this study, patients must completed questionnaires of quality of life. Questionnaires should be completed by the patient Electronic Patient Reported Outcome (ePRO)at each applicable occasion. Where possible in accordance with local clinical practice, PROs should be completed before other assessments. The following measures are requested to be recorded:
* EORTC-QLQ-C30 (Version 3).
* EORTC QLQ NHL-HG29
The standardized EORTC QLQ-C30 questionnaire (v. 3.0) was used to assess the HRQoL of cancer patients. The questionnaire contains questions regarding the impact of the disease on different areas of a patient's life (physical, role, emotional, cognitive, and social functioning), the occurrence of symptoms (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea), financial difficulties, and an overall assessment of HRQoL (Appendix 4). (Aaronson NK, Ahmedzai S, Bergman B, et al. 1993). For each question, the respondent must choose 1 answer. For 28 of the questions, the answers are given on a 4-point Likert-type scale (1 - never, 2 - sometimes, 3 - often, 4 - very often) and assess the intensity of the analysed parameters. The last 2 questions evaluate the general health of the patient on a 7-point scale (from 1 - very bad to 7 - excellent). Patients completed the questionnaires by themselves. If a question arose, they could ask the researcher for an explanation.
After collecting the responses, a raw score was calculated for each of the abovementioned 15 questionnaire items. Next, a linear transformation was performed to obtain a score in a range from 0 to 100. The conversion of the results to a 100-point scale was made according to the EORTC guidelines. Of note, a higher score on the functional scales means better functioning and a higher response for general health corresponds to a better HRQoL.
The QLQ-HG-NHL29 consists of 29 items, contributing to five multiitem subscales and three conditional items: symptom burden due to disease and/or treatment (seven items), neuropathy (two items), physical condition/fatigue (five items), emotional impacts (four items) and worries about health and functioning (eight items). The three conditional items, which patients complete only if relevant to them, are about having problems at work/education, worries about work/education and concerns about the ability to have children. (Appendix 5) (Van de Poll-Franse L, Oerlemans S, Bredart A, et al. 2018) Items are rated using a four-point response scale ("not at all," "a little," "quite a bit," and "very much") and the reference time frame for all items is the past week.14 The scoring approach for the QLQ-HG-NHL29 is identical to that of the EORTC QLQ-C30, i.e., calculating the mean of the items of a specific multi-item scale or using the single conditional item score and then converting it into a standardized scale ranging from 0 to 100. A higher score for all the multi-item scales and items represent a higher level of symptomatology or problems.
HRQoL questionnaires will be filled out either at the hospital or during pre-scheduled medical office visits. The questionnaires will be provided to the patient by a member of the study team at the scheduled times to coincide with other scheduled assessments or visits, via standard paper copy administration. However, HRQoL electronic questionnaires administration may be allowed as a back-up procedure, to maximize compliance. Patients will be asked to fill out the questionnaires as completely and accurately as possible with an expected average time of completion around 10 minutes.
A high compliance with HRQoL questionnaires throughout the study period is considered essential for the success of this observational study and local Investigators of participating centers will have to be properly informed and motivated towards the importance of collecting HRQoL data.
Each participating center will be requested to submit a HRQoL Missing Data Form in lieu of a HRQoL questionnaire for any assessment that is not provided at the appropriate follow-up time point. Compliance with HRQoL questionnaires over time will be monitored (not for the purpose of informing clinical care of participants) and, if needed, reminders will be sent to participating centers to solicit HRQoL data. The compliance rate at each time point will be evaluated as the number of valid HRQoL questionnaires returned by eligible patients as a proportion of the total number of eligible patients available.
In order to make the HRQoL component of the study as pragmatic as possible, and not to undermine the data collection process across several centers, HRQoL assessment is requested to take place in conjunction with the collection of effectiveness data foreseen for this protocol.
Therefore, HRQoL questionnaires will be administered at baseline (before first tafasitamab administration) and then every 3 months during the first year, and then every 6 months thereafter, unless the patient has a disease progression and/or permanently discontinue treatment with tafasitamab. The first HRQoL assessment after baseline, would correspond to the end of the period where tafasitamab is administered on a weekly basis (approximately at the end of cycle 3), hence with potential expected HRQoL detriments. Thereafter, (starting from cycle 4) considering the infusions of tafasitamab will take place every 2 weeks, HRQoL improvements (although with not known magnitude) could possibly be expected and captured in this study. HRQoL will be assessed regardless of dose modification or temporary treatment interruption, as long as the patient is considered "on study" according current protocol definition.
In case of temporary treatment interruption:
Continue HRQoL assessment as described in the above schedule of administration.
In case of permanent treatment discontinuation with tafasitamab:
HRQoL assessment should be performed at the time of discontinuation (in any case as close as possible to the time of treatment discontinuation) and then stopped afterwards.
In case of disease progression:
HRQoL assessment should be performed at the time of progression (in any case as close as possible to the time of disease progression) and then stopped afterwards.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
DLBCL - Diffuse Large B Cell Lymphoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single group/cohort
Patients with DLBCL R/R disease non-transplant eligible
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients are aged 18 years or older.
2. Patients with DLBCL R/R disease non-transplant eligible.
3. Patients who will initiate the treatment with commercially available tafasitamab and lenalidomide after the ICF signature. The decision to prescribe tafasitamab must have been made prior and regardless of the enrollment of the patient in the study.
4. Patients are able of giving the signed informed consent.
2. Patients with DLBCL R/R disease non-transplant eligible.
3. Patients who will initiate the treatment with commercially available tafasitamab and lenalidomide after the ICF signature. The decision to prescribe tafasitamab must have been made prior and regardless of the enrollment of the patient in the study.
4. Patients are able of giving the signed informed consent.
Exclusion Criteria
1. Concomitant participation in an interventional clinical study
2. Any patient in the physician's opinion from whom initial diagnosis or follow-up data is unlikely to be obtained reliably data for the purposes of this observational study.
3. Patients who started tafasitamab treatment before signing the ICF.
2. Any patient in the physician's opinion from whom initial diagnosis or follow-up data is unlikely to be obtained reliably data for the purposes of this observational study.
3. Patients who started tafasitamab treatment before signing the ICF.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advice Pharma Group srl
INDUSTRY
Sponsor Role
collaborator
Incyte Biosciences Italy S.r.l
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Incyte Biosciences Italy S.r.l
Milan, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zinzani PL, Minotti G. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Jan;148(1):177-190. doi: 10.1007/s00432-021-03833-x. Epub 2021 Nov 6.
Reference Type
BACKGROUND
Duell, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, E.G., Jurczak, W., Kalakonda, N., Liberati, A.M., Maddocks, K.J., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K. and Salles, G. (2023), Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L-MIND study. Hematological Oncology, 41: 437-439
Reference Type
BACKGROUND
Calamia M, McBride A, Abraham I. Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL. J Med Econ. 2021 Nov;24(sup1):14-24. doi: 10.1080/13696998.2021.2007704.
Reference Type
BACKGROUND
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
Reference Type
BACKGROUND
van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniels L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB88888-040 PRO-MIND
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
NCT00799513
COMPLETED
PHASE2
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Indolent Non Follicular Lymphomas Prognostic Project
NCT02904577
COMPLETED
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT05351593
RECRUITING
PHASE1/PHASE2
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NCT07030699
RECRUITING
PHASE2
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
NCT02399085
COMPLETED
PHASE2
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
NCT04134936
COMPLETED
PHASE1
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT06835530
RECRUITING
PHASE2
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
RECRUITING
PHASE2
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
NCT02955823
COMPLETED
PHASE2
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255
RECRUITING
PHASE3
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194
RECRUITING
PHASE2
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT04974216
ACTIVE_NOT_RECRUITING
PHASE2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156
RECRUITING
PHASE2
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT04809467
COMPLETED
PHASE1/PHASE2
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)
NCT05746858
NOT_YET_RECRUITING
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT05883709
UNKNOWN
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05788289
TERMINATED
PHASE2
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
NCT05328102
TERMINATED
PHASE2
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
NCT00907348
UNKNOWN
PHASE2
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
NCT05541341
RECRUITING
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02142049
COMPLETED
PHASE1/PHASE2